Invesco’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.6M | Buy |
523,711
+49,636
| +10% | +$1.48M | ﹤0.01% | 1592 |
|
|
2025
Q4 | $18.1M | Sell |
474,075
-153,827
| -24% | -$5M | ﹤0.01% | 1517 |
|
|
2025
Q3 | $15M | Buy |
627,902
+116,983
| +23% | +$2.2M | ﹤0.01% | 1595 |
|
|
2025
Q2 | $7.56M | Sell |
510,919
-55,008
| -10% | -$912K | ﹤0.01% | 1955 |
|
|
2025
Q1 | $10.1M | Sell |
565,927
-293,015
| -34% | -$5.95M | ﹤0.01% | 1787 |
|
|
2024
Q4 | $15M | Buy |
858,942
+493,736
| +135% | +$8.73M | ﹤0.01% | 1632 |
|
|
2024
Q3 | $5.11M | Buy |
365,206
+334,226
| +1,079% | +$3.48M | ﹤0.01% | 2210 |
|
|
2024
Q2 | $255K | Sell |
30,980
-2,207
| -7% | -$14.9K | ﹤0.01% | 3546 |
|
|
2024
Q1 | $256K | Sell |
33,187
-21,800
| -40% | -$184K | ﹤0.01% | 3570 |
|
|
2023
Q4 | $494K | Sell |
54,987
-758,265
| -93% | -$5.52M | ﹤0.01% | 3225 |
|
|
2023
Q3 | $7.27M | Buy |
813,252
+113,250
| +16% | +$1.6M | ﹤0.01% | 1976 |
|
|
2023
Q2 | $10.8M | Buy |
700,002
+149,546
| +27% | +$2.72M | ﹤0.01% | 1767 |
|
|
2023
Q1 | $12.4M | Sell |
550,456
-6,220
| -1% | -$132K | ﹤0.01% | 1631 |
|
|
2022
Q4 | $11.7M | Buy |
556,676
+119,090
| +27% | +$2.52M | ﹤0.01% | 1746 |
|
|
2022
Q3 | $10.8M | Sell |
437,586
-61,900
| -12% | -$1.6M | ﹤0.01% | 1739 |
|
|
2022
Q2 | $12.1M | Buy |
499,486
+100,129
| +25% | +$2.52M | ﹤0.01% | 1708 |
|
|
2022
Q1 | $10.3M | Sell |
399,357
-111,844
| -22% | -$2.97M | ﹤0.01% | 1943 |
|
|
2021
Q4 | $15.9M | Buy |
511,201
+474,229
| +1,283% | +$13.4M | ﹤0.01% | 1701 |
|
|
2021
Q3 | $897K | Buy |
36,972
+2,868
| +8% | +$52.7K | ﹤0.01% | 3157 |
|
|
2021
Q2 | $497K | Sell |
34,104
-356,987
| -91% | -$7.04M | ﹤0.01% | 3427 |
|
|
2021
Q1 | $9.77M | Buy |
391,091
+360,928
| +1,197% | +$9.97M | ﹤0.01% | 1964 |
|
|
2020
Q4 | $822K | Sell |
30,163
-475,762
| -94% | -$11.1M | ﹤0.01% | 3020 |
|
|
2020
Q3 | $9.34M | Sell |
505,925
-116,177
| -19% | -$2.26M | ﹤0.01% | 1688 |
|
|
2020
Q2 | $12.7M | Buy |
622,102
+595,456
| +2,235% | +$9.48M | ﹤0.01% | 1514 |
|
|
2020
Q1 | $389K | Buy |
26,646
+9,349
| +54% | +$141K | ﹤0.01% | 3163 |
|
|
2019
Q4 | $246K | Sell |
17,297
-1,104
| -6% | -$14.1K | ﹤0.01% | 3483 |
|
|
2019
Q3 | $213K | Sell |
18,401
-1,064,209
| -98% | -$17.6M | ﹤0.01% | 3535 |
|
|
2019
Q2 | $21.8M | Buy |
1,082,610
+12,631
| +1% | +$249K | 0.01% | 1386 |
|
|
2019
Q1 | $24.2M | Buy |
1,069,979
+10,663
| +1% | +$236K | 0.01% | 1124 |
|
|
2018
Q4 | $24M | Sell |
1,059,316
-517,525
| -33% | -$12.9M | 0.01% | 1064 |
|
|
2018
Q3 | $45.3M | Buy |
1,576,841
+540,987
| +52% | +$15.5M | 0.01% | 896 |
|
|
2018
Q2 | $28.2M | Sell |
1,035,854
-710,020
| -41% | -$18.9M | 0.01% | 1054 |
|
|
2018
Q1 | $39M | Buy |
1,745,874
+689,291
| +65% | +$16.4M | 0.01% | 853 |
|
|
2017
Q4 | $22.3M | Sell |
1,056,583
-111,578
| -10% | -$2.55M | 0.01% | 1163 |
|
|
2017
Q3 | $29.1M | Buy |
1,168,161
+29,852
| +3% | +$657K | 0.01% | 1005 |
|
|
2017
Q2 | $22.1M | Buy |
1,138,309
+28,064
| +3% | +$509K | 0.01% | 1145 |
|
|
2017
Q1 | $20.5M | Sell |
1,110,245
-3,470
| -0.3% | -$67.9K | 0.01% | 1167 |
|
|
2016
Q4 | $21.1M | Sell |
1,113,715
-16,149
| -1% | -$330K | 0.01% | 1136 |
|
|
2016
Q3 | $25.3M | Sell |
1,129,864
-40,219
| -3% | -$766K | 0.01% | 1073 |
|
|
2016
Q2 | $20.8M | Buy |
1,170,083
+406,257
| +53% | +$6.58M | 0.01% | 1121 |
|
|
2016
Q1 | $10.4M | Buy |
763,826
+7,428
| +1% | +$113K | ﹤0.01% | 1414 |
|
|
2015
Q4 | $14.6M | Buy |
756,398
+31,994
| +4% | +$639K | 0.01% | 1301 |
|
|
2015
Q3 | $14.7M | Buy |
724,404
+484,981
| +203% | +$14.4M | 0.01% | 1279 |
|
|
2015
Q2 | $7.94M | Buy |
239,423
+169,707
| +243% | +$4.65M | ﹤0.01% | 1675 |
|
|
2015
Q1 | $1.67M | Buy |
+69,716
| New | +$1.06M | ﹤0.01% | 2726 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
Invesco's TVTX Position: Q1 2026 in Review
Invesco increased its Travere Therapeutics (TVTX) stake by 10% in Q1 2026, buying an estimated $1.48M and bringing the position to 523,711 shares worth $15.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1592.
Invesco first reported a position in TVTX in Q1 2015 and has held it in 45 quarters since. The position peaked at $45.3M in Q3 2018. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- Invesco held 523,711 shares of Travere Therapeutics worth $15.6M as of Q1 2026.
- Invesco bought 49,636 Travere Therapeutics shares in Q1 2026, an estimated $1.48M.
- Travere Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #1592 holding.
- Invesco first reported a position in Travere Therapeutics in Q1 2015 and has held it in 45 quarters since.
- Invesco's Travere Therapeutics position peaked at $45.3M in Q3 2018.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.